3-(2-bromoethyl)-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one | 85623-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑四嗪类
• 英文名称: 3-(2-bromoethyl)-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one
• 英文别名: 3-(2-Bromoethyl)-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
• CAS: 85623-01-4
• 化学式: C₇H₇BrN₆O₂
• 分子量: 287.076
• InChiKey: PVTYYSITCCDJEY-UHFFFAOYSA-N

物化性质

• 沸点：
  566.6±56.0 °C(Predicted)
• 密度：
  2.24±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxylic Acid Amides and Their Use
  申请人：Stevens Malcolm Francis Graham

  公开号：US20100286088A1

  公开（公告）日：2010-11-11

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及某些3-取代-4-氧代-3,4-二氢咪唑[5,1-d][1,2,3,5]四嗪-8-羧酸酰胺（统称为3TM化合物）。本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，在治疗增生性疾病如癌症等方面的应用，以及制备这种化合物的方法。
• METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Kolhe Parag

  公开号：US20100143340A1

  公开（公告）日：2010-06-10

  The present invention provides methods for preventing or treating a medical disorder in a subject comprising administering to the subject an effective amount of a stable pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof.

  本发明提供了一种预防或治疗受试者医疗障碍的方法，包括向受试者投与一种包含抗体或其抗原结合片段的稳定药物制剂的有效量。
• Methods and Means for the Treatment of Cancer
  申请人：Van Tellingen Olaf

  公开号：US20090170880A1

  公开（公告）日：2009-07-02

  Provided are Breast Cancer Resistance Protein (BCRP) inhibitors, P-glycoprotein (P-gp) inhibitors and chemotherapeutic agents for use in the treatment of cancer by combination therapy of the BCRP inhibitor and/or P-gp inhibitor with the chemotherapeutic agent. The chemotherapeutic agent is an imidazotetrazine, e.g. temozolomide.
• US5260291A
  申请人：——

  公开号：US5260291A

  公开（公告）日：1993-11-09
• US8450479B2
  申请人：——

  公开号：US8450479B2

  公开（公告）日：2013-05-28